Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist

References

• Abuhelwa AY, Williams DB, Upton RN, Foster DJ. 2017. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 112:234–248.
   PubMed Web of Science ®Google Scholar
• Ali M, Raslan M, Ciebiera M, Zaręba K, Al-Hendy A. 2022. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 21(4):477–486.
   PubMed Web of Science ®Google Scholar
• Brouwers JR, Van der Kam HJ, Sijtsma J, Proost JH. 1990. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. Pharm Weekbl Sci. 12(5):182–183.
   PubMedGoogle Scholar
• Campbell NR, Hasinoff BB. 1991. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol. 31(3):251–255.
   PubMed Web of Science ®Google Scholar
• Chen ZJ, Zhang J, Yu JC, Cao GY, Wu XJ, Shi YG. 2006. Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandam mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 834(1-2):163–169.
   PubMed Web of Science ®Google Scholar
• Ciarmela P, Critchley H, Christman GM, Reis FM. 2013. Pathogenesis of endometriosis and uterine fibroids. Obstet Gynecol Int. 2013(656571):1–2.
   Google Scholar
• Dababou S, Garzon S, Laganà AS, Ferrero S, Evangelisti G, Noventa M, D'Alterio MN, Palomba S, Uccella S, Franchi M, et al. 2021. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 30(9):903–911.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. 2021. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review. JCM. 10(5):1085.
   Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. 2020. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 114(1):44–55.
   PubMed Web of Science ®Google Scholar
• [EMA] European medicines agency 2012. Guideline on the investigation of drug interactions. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
   Google Scholar
• Flake GP, Andersen J, Dixon D. 2003. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 111(8):1037–1054.
   PubMed Web of Science ®Google Scholar
• Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT. 1992. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 36(4):830–832.
   PubMed Web of Science ®Google Scholar
• Giudice LC. 2010. Clinical practice. Endometriosis. N Engl J Med. 362(25):2389–2398.
   PubMed Web of Science ®Google Scholar
• Gugler R, Allgayer H. 1990. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet. 18(3):210–219.
   PubMed Web of Science ®Google Scholar
• Gunnarsson PO, Davidsson T, Andersson SB, Backman C, Johansson SA. 1990. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 38(2):189–193.
   PubMed Web of Science ®Google Scholar
• ICH guideline. 2022 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Drug interaction studies M12. https://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdf
   Google Scholar
• Jantratid E, Janssen N, Reppas C, Dressman JB. 2008. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 25(7):1663–1676.
   PubMed Web of Science ®Google Scholar
• Jin HE, Kim IB, Kim CK, Maeng HJ. 2013. Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir. Biomed Chromatogr. 27(11):1423–1430.
   PubMed Web of Science ®Google Scholar
• Kato R, Ooi K, Ikura-Mori M, Tsuchishita Y, Hashimoto H, Yoshimura H, Uenishi K, Kawai M, Tanaka K, Ueno K. 2002a. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol. 42(11):1275–1280.
   PubMed Web of Science ®Google Scholar
• Kato R, Ooi K, Takeda K, Mashimo K, Fujimura Y, Kusumoto M, Ueno K. 2002b. Lack of interaction between cefdinir and calcium polycarbophil: in vitro and in vivo studies. Drug Metab Pharmacokinet. 17(4):363–366.
   PubMedGoogle Scholar
• Kato R, Ueno K, Imano H, Kawai M, Kuwahara S, Tsuchishita Y, Yonezawa E, Tanaka K. 2002c. Impairment of ciprofloxacin absorption by calcium polycarbophil. J Clin Pharmacol. 42(7):806–811.
   PubMed Web of Science ®Google Scholar
• Khan A, Iqbal Z, Khan MI, Javed K, Khan A, Ahmad L, Shah Y, Nasir F. 2011. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 879(24):2423–2429.
   PubMed Web of Science ®Google Scholar
• Kokado Y, Kawai K, Nanjo T, Kinoshita S, Kondo K. 2021. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. Clin Ther. 43(8):1408–1418.e5.
   PubMed Web of Science ®Google Scholar
• Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, et al. 2019. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. Eur J Pharm Sci. 134:31–59.
   PubMed Web of Science ®Google Scholar
• Leyden JJ. 1985. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol. 12(2 Pt 1):308–312.
   PubMed Web of Science ®Google Scholar
• Li J, Wang L, Chen Z, Xie R, Li Y, Hang T, Fan G. 2012. Development and validation of a rapid HPLC method for the determination of cefdinir in beagle dog plasma integrated with an automatic on-line solid-phase extraction following protein precipitation in the 96-well plate format. J Chromatogr B Analyt Technol Biomed Life Sci. 895-896:83–88.
   PubMed Web of Science ®Google Scholar
• Milman NT. 2020. A Review of Nutrients and Compounds, Which Promote or Inhibit Intestinal Iron Absorption: Making a Platform for Dietary Measures That Can Reduce Iron Uptake in Patients with Genetic Haemochromatosis. J Nutr Metab. 2020:7373498.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour, and Welfare 2018. Guideline on drug interaction for drug development and appropriate provision of information. https://www.pmda.go.jp/files/000228122.pdf
   Google Scholar
• Mizuki Y, Fujiwara I, Yamaguchi T. 1996. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 37(Suppl A):41–55.
   PubMed Web of Science ®Google Scholar
• Mooney MT, Deguchi S, Tada T, Fujioka M, Okamoto Y, Yasuda T. 1995. Interaction of cefdinir with iron in aqueous solution. Chem Pharm Bull. 43(3):374–377.
   Web of Science ®Google Scholar
• Nakano M, Yamamoto M, Arita T. 1978. Interactions of aluminum, magnesium, and calcium ions with nalidixic acid. Chem Pharm Bull (Tokyo)). 26(5):1505–1510.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. 1976. Interactions with the absorption of tetracyclines. Drugs. 11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, De Sarro G, Gallelli L. 2013. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 18(7):601–610.
   PubMed Web of Science ®Google Scholar
• Pitman SK, Hoang UTP, Wi CH, Alsheikh M, Hiner DA, Percival KM. 2019. Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant? Antibiotics (Basel.). 8(3):108.
   Web of Science ®Google Scholar
• Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E. 2018. Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109. J Clin Endocrinol Metab. 103(2):497–504.
   PubMed Web of Science ®Google Scholar
• Segars JH, Parrott EC, Nagel JD, Guo XC, Gao X, Birnbaum LS, Pinn VW, Dixon D. 2014. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum Reprod Update. 20(3):309–333.
   PubMed Web of Science ®Google Scholar
• Shon J, Zou P, Tran D, Seo SK, Lu Y. 2020. Clinical Pharmacology at the Intersection of Women's Health and Regulation: Drug Development Considerations for Uterine Fibroids. J Clin Pharmacol. 60(Suppl 2):S39–S48.
   PubMed Web of Science ®Google Scholar
• Sultana N, Arayne MS, Hussain F. 2005. In vitro monitoring of ciprofloxacin antacids interactions by UV & HPLC. Pak J Pharm Sci. 18(4):23–31.
   PubMedGoogle Scholar
• Tezuka M, Tamai Y, Kuramochi Y, Kobayashi K, Fushimi N, Kiguchi S. 2022. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors. Clin Exp Pharmacol Physiol. doi:10.1111/1440-1681.13688
   PubMed Web of Science ®Google Scholar
• Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. 2011. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 100(12):5324–5345.
   PubMed Web of Science ®Google Scholar
• U.S. FDA. 2002. Guidance for industry food-effect bioavailability and fed bioequivalence studies. https://www.fda.gov/media/70945/download
   Google Scholar
• U.S. FDA. 2020. In Vitro Drug Interaction Studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https://www.fda.gov/media/134582/download
   Google Scholar
• Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I. 1993. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther. 54(5):473–475.
   PubMed Web of Science ®Google Scholar
• Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM. 2009. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 31(4):764–776.
   PubMed Web of Science ®Google Scholar